Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Symfony Toric IOL.
Cataracts are a common condition, with almost 4 million cataract surgeries performed each year, and that number is expected to increase.1 By age 80, more than half of all Americans either have a cataract or have had cataract surgery.2 However, cataracts do not just impact seniors. In 2016 it is estimated that nearly one in four cataract surgeries will be performed on people younger than 65.1 Many people who have cataracts experience other problems with their vision, such as presbyopia and astigmatism, which the Symfony lenses also address. Presbyopia, which affects most people over age 40, means people have lost the ability to focus on objects up close and often require glasses to perform near visual tasks. Astigmatism is when the cornea is misshapen, which causes blurry or distorted vision.
To view the multimedia release go to:
http://www.multivu.com/players/English/7870151-abbott-intraocular-lenses/
Nationally-recognized and long-standing sports announcer Jerry Punch, M.D., is teaming up with Men’s Health Network and Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), to launch “Ask About the Curve,” a new educational campaign designed to raise awareness of Peyronie’s disease. Peyronie’s disease is a little-known men’s health condition that can occur during midlife or later. And, while the disease is physical in nature, the impact may also be psychological and could possibly hold men back from talking about it.
Peyronie’s disease, or “PD,” is a condition that can cause curvature of the penis that could be painful during arousal and intimacy. It can affect as many as one in 10 men worldwide, but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help. Together with Endo and Men’s Health Network, Dr. Punch is encouraging men who think they might have PD to face their challenge head on by starting the conversation with their doctor.
“As a sports commentator, I’ve witnessed thousands of men on the court, on the field and on the racetrack in their physical prime – cool, confident and thriving in the face of challenge. But, as a licensed physician, I’ve seen how this bravado can turn to embarrassment – even isolation – when that challenge becomes personal or intimate,” said Dr. Punch. “Often, men feel too awkward to talk about issues like Peyronie’s disease, even with a doctor. And while it may seem tough, it’s important that any man with PD see a doctor, and ask about the curve. Starting the conversation is the first step to getting help.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7752151-ask-about-the-curve-psa/
The Pinch Arete on the Wellington Block at Harrisons Rocks,Birchden Wood,Groombridge.The route was very damp on this day but on a warmer day is excellent.
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Eisai Inc. today announced the launch of My Healthy™, an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained. Almost 70 percent of Americans are affected by obesity or overweight. This movement emphasizes that those affected by obesity or overweight with a related health condition can benefit from small positive changes, including modest weight loss.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7131331-eisai-inc-my-healthy-promise-liberate-your-closet/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Most people are deficient in vitamin D3. You can supplement with 2000, 5000, or 10,000 IU of vitamin D3 but that may not be enough. The only way to tell if your blood has an adequate amount of D3 is to have a blood test for D3 and have your doctor examine the results.
Top of the mountain, five percent battery remaining, no outlet in sight. Decision time: go back or keep going? Adventurers can now go further in almost any condition with FRĒ Power from LifeProof, doubling the battery life of iPhone 6.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7525051-lifeproof-announces-fre-power/
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
Next week at the Consumer Electronics Showcase (CES) in Las Vegas, Neutrogena® will debut sophisticated skin imaging technology that allows consumers to measure what’s happening above and below their skin’s surface. The Neutrogena Skin360™ app and the accompanying SkinScanner powered by FitSkin™ give users an in depth understanding of their skin’s condition and needs, customized advice to address those needs, plus a clear way to track and assess skin’s progress over time.
“Shopping for skincare products can be an overwhelming and confusing experience for our consumer because she is uncertain about what her skin really needs,” said Sebastien Guillon, Global President of Beauty, Johnson & Johnson Consumer. “Smart and connected technology helps us provide our consumer with personalized analyses and information she needs in real time so she can make decisions that will help her achieve her best skin ever.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8250251-neutrogena-skin360-skinscanner-fitskin-ces/
